Immunoregulatory Networks in Chlamydia Genital Tract Infection

衣原体生殖道感染的免疫调节网络

基本信息

  • 批准号:
    7991844
  • 负责人:
  • 金额:
    $ 13.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-12-25 至 2013-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Amy Scurlock, M.D., is an Assistant Professor who completed her Allergy/Immunology Fellowship in 2004. In this application, she describes a multi-faceted, 5-year research and educational training program that will expand her scientific skills by integrating the enthusiastic mentorship of her experienced sponsor, Dr. Roger Rank, and scientific advisory committee with numerous institutional resources. Sexually transmitted infections (STI) with Chlamydia trachomatis are the most common bacterial STI in both the United States and worldwide and represent a significant public health concern. At present, there are no biomarkers to predict potentially devastating reproductive complications, such as infertility and ectopic pregnancy, associated with Chlamydia infections. The research plan will evaluate the expanding diversity of effector and regulatory CD4+ T-cell responses following Chlamydia infection. The central hypothesis proposes that the CD4+ Th17 lineage is a pathologic CD4+ effector response that promotes reproductive tract pathology following Chlamydia genital tract infection. Employing a series of in vivo experiments in an established mouse model, the hypothesis will be tested by the following Specific Aims: 1) Determine the role of the Th17 response in development of reproductive tract pathology following chlamydial genital tract infection, 2) Examine the interaction between Th17 and T-regulatory cells in modulating the outcome of Chlamydia genital tract infection. Information gained from the proposed studies will advance Dr. Scurlock's immediate and long-term career objectives to expand her technical and analytical research skills, develop biomarkers for adverse disease outcomes following Chlamydia STI, and translate findings in the basic immunology laboratory into clinically relevant prevention and intervention strategies for STI. The PI will take advantage of strong mentoring, protected research time, and outstanding academic resources at the University of Arkansas for Medical Sciences and the Arkansas Children's Hospital Research Institute to reach her goal of becoming an independent investigator with an established scientific niche in genital tract mucosal immunology. RELEVANCE: Sexually transmitted Chlamydia trachomatis infections are a significant public health problem due to their high frequency and risk of reproductive complications including infertility and ectopic pregnancy. This project evaluates the newly described T-helper 17 response as an important contributor to Chlamydia-induced reproductive tract tissue damage.
描述(由申请人提供):Amy Scurlock,医学博士,她是一名助理教授,于2004年完成了过敏/免疫学奖学金。在这份申请中,她描述了一个多方面的,为期5年的研究和教育培训计划,将通过整合她的经验丰富的赞助商,博士的热情指导来扩大她的科学技能。沙眼衣原体性传播感染(STI)是美国和世界范围内最常见的细菌性STI,是一个重大的公共卫生问题。目前,还没有生物标志物来预测潜在的破坏性生殖并发症,如不孕症和宫外孕,与衣原体感染有关。该研究计划将评估衣原体感染后效应和调节CD 4 + T细胞反应的多样性。中心假说提出,CD 4 + Th 17谱系是一种病理性CD 4+效应反应,促进生殖道衣原体感染后的生殖道病理。在已建立的小鼠模型中进行一系列体内实验,该假设将通过以下特定目的进行检验:1)确定Th 17反应在衣原体生殖道感染后生殖道病理发展中的作用,2)检查Th 17之间的相互作用和调节性T细胞调节衣原体生殖道感染的结果。从拟议的研究中获得的信息将推进Scurlock博士的近期和长期职业目标,以扩大她的技术和分析研究技能,开发衣原体STI后不良疾病结果的生物标志物,并将基础免疫学实验室的发现转化为临床相关的STI预防和干预策略。PI将利用阿肯色州大学医学科学和阿肯色州儿童医院研究所的强大指导、受保护的研究时间和优秀的学术资源,以实现她成为一名独立研究者的目标,并在生殖道粘膜免疫学领域建立科学利基。相关性:性传播的沙眼衣原体感染是一个重大的公共卫生问题,因为它们的高频率和生殖并发症,包括不孕症和异位妊娠的风险。该项目评估了新描述的T辅助细胞17反应作为衣原体诱导的生殖道组织损伤的重要贡献者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AMY M. SCURLOCK其他文献

AMY M. SCURLOCK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AMY M. SCURLOCK', 18)}}的其他基金

Immunoregulatory Networks in Chlamydia Genital Tract Infection
衣原体生殖道感染的免疫调节网络
  • 批准号:
    8196982
  • 财政年份:
    2008
  • 资助金额:
    $ 13.23万
  • 项目类别:
Immunoregulatory Networks in Chlamydia Genital Tract Infection
衣原体生殖道感染的免疫调节网络
  • 批准号:
    7588300
  • 财政年份:
    2008
  • 资助金额:
    $ 13.23万
  • 项目类别:
Immunoregulatory Networks in Chlamydia Genital Tract Infection
衣原体生殖道感染的免疫调节网络
  • 批准号:
    8389650
  • 财政年份:
    2008
  • 资助金额:
    $ 13.23万
  • 项目类别:
Immunoregulatory Networks in Chlamydia Genital Tract Infection
衣原体生殖道感染的免疫调节网络
  • 批准号:
    7753218
  • 财政年份:
    2008
  • 资助金额:
    $ 13.23万
  • 项目类别:
Project 2 - Regulation of the T-cell Memory Response in Chlamydia Genital Tract
项目 2 - 衣原体生殖道 T 细胞记忆反应的调节
  • 批准号:
    8460760
  • 财政年份:
  • 资助金额:
    $ 13.23万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 13.23万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 13.23万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 13.23万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 13.23万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 13.23万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 13.23万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 13.23万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 13.23万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 13.23万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 13.23万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了